AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38982400 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anaesthesia
Number of subjects: 163
Study 38982486 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum TMAO levels
Number of subjects: 1964
Study 38982528 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin glargine 300 U/mL (Gla-300)
Number of subjects: 123
Study 38982551 — intervention group
Group type: EXPERIMENTAL
Intervention: High plasma calprotectin on admission and day 7
Number of subjects: 498
Study 38982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing calprotectin from admission to day 7
Number of subjects: 498
Study 38982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 calprotectin and age
Number of subjects: 498
Study 38982551 — intervention group
Group type: EXPERIMENTAL
Intervention: Day 7 calprotectin alone
Number of subjects: 498
Study 38982653 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 2.50 mg/kg QW
Number of subjects: 182
Study 38982653 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 150 mg QW
Number of subjects: 182
Study 38982653 — intervention group
Group type: EXPERIMENTAL
Intervention: Envafolimab 300 mg Q2W
Number of subjects: 182
Study 38982653 — intervention group
Group type: COMPARATOR
Intervention: Weight-based dosing regimen
Number of subjects: 182
Study 38982653 — intervention group
Group type: COMPARATOR
Intervention: Fixed dose regimen
Number of subjects: 182
Study 38982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modality A
Number of subjects: 0
Study 38982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment modality B
Number of subjects: 0
Study 38982903 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 0
Study 38983151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg orally twice daily until disease progression or unacceptable toxicity
Number of subjects: 20
Study 38983151 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 20
Study 38983158 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam 20 mg administered before surgical incision and at the end of surgery during chest tube insertion.
Number of subjects: 46
Study 38983158 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 100 mL administered as control.
Number of subjects: 46
Study 38983542 — intervention group
Group type: EXPERIMENTAL
Intervention: iOCT-guided DMEK surgery
Number of subjects: 65
Study 38983542 — intervention group
Group type: COMPARATOR
Intervention: Control group without iOCT-use
Number of subjects: 65
Study 38983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty assessment using Timed Up and Go (TUG) and Short Physical Performance Battery (SPPB) tests
Number of subjects: 135
Study 38983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Incorporating SPPB, especially the balance test
Number of subjects: 135
Study 38983653 — intervention group
Group type: EXPERIMENTAL
Intervention: Effective identification and management of frailty
Number of subjects: 135
Study 38983729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (4 mg)
Number of subjects: 8
Study 38983729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (2 mg)
Number of subjects: 8
Study 38983729 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 38983729 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilaprisan (4 mg and 2 mg)
Number of subjects: 8
Study 38983736 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin α (weekly continuous dosing)
Number of subjects: 15
Study 38983736 — intervention group
Group type: COMPARATOR
Intervention: Daily follicle-stimulating hormone protocol (control)
Number of subjects: 15
Study 38983921 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam-based total intravenous anesthesia
Number of subjects: 0
Study 38983921 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based inhalation anesthesia
Number of subjects: 0
Study 38984118 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD supplement (lutein 20 mg, zeaxanthin isomers 4 mg, curcumin 200 mg, vitamin D3 600 IU)
Number of subjects: 155
Study 38984118 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD supplement
Number of subjects: 155
Study 38984118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 38984984 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning algorithm using MRI and clinical data to predict neurodevelopmental outcomes
Number of subjects: 0
Study 38984984 — intervention group
Group type: COMPARATOR
Intervention: MRI data analysis
Number of subjects: 0
Study 38985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 1441
Study 38985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 1441
Study 38985161 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 1441
Study 38985161 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin 100 mg
Number of subjects: 1441
Study 38985162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 3 mg
Number of subjects: 521
Study 38985162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 7 mg
Number of subjects: 521
Study 38985162 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide 14 mg
Number of subjects: 521
Study 38985162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 521
Study 38985175 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization (length of stay)
Number of subjects: 110
Study 38985175 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement follow-up
Number of subjects: 110
Study 38985220 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-pectoral IBR
Number of subjects: 78
Study 38985220 — intervention group
Group type: COMPARATOR
Intervention: Sub-pectoral IBR
Number of subjects: 78
Study 38985232 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 56
Study 38985232 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 56
Study 38985247 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib (FIL) 200 mg + MTX/csDMARD
Number of subjects: 3365
Study 38985247 — intervention group
Group type: COMPARATOR
Intervention: Placebo + MTX / Placebo + csDMARD
Number of subjects: 3365
Study 38985303 — intervention group
Group type: EXPERIMENTAL
Intervention: CaRE-4-alloBMT rehabilitation program
Number of subjects: 80
Study 38985408 — intervention group
Group type: EXPERIMENTAL
Intervention: SE travoprost intracameral implant
Number of subjects: 133
Study 38985408 — intervention group
Group type: COMPARATOR
Intervention: Topical PGA monotherapy
Number of subjects: 133
Study 38985408 — intervention group
Group type: COMPARATOR
Intervention: SE travoprost intracameral implant vs. Topical PGA monotherapy
Number of subjects: 133
Study 38985436 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimegepant 75 mg, orally, up to once daily for up to 52 weeks
Number of subjects: 1800
Study 38985445 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir + Rilpivirine long-acting (CAB + RPV LA) dosed every 2 months (Q2M)
Number of subjects: 430
Study 38985461 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 mg once daily
Number of subjects: 2966
Study 38985461 — intervention group
Group type: COMPARATOR
Intervention: Edoxaban 30 mg once daily
Number of subjects: 2966
Study 38985461 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 2966
Study 38985474 — intervention group
Group type: COMPARATOR
Intervention: Feedback
Number of subjects: 2020
Study 38985474 — intervention group
Group type: COMPARATOR
Intervention: Standard incentive
Number of subjects: 2020
Study 38985474 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard incentive plus feedback
Number of subjects: 2020
Study 38985474 — intervention group
Group type: EXPERIMENTAL
Intervention: Reframed incentive plus feedback
Number of subjects: 2020
Study 38985474 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubled reframed incentive plus feedback
Number of subjects: 2020
Study 38985475 — intervention group
Group type: EXPERIMENTAL
Intervention: Take Good Care (TGC) intervention
Number of subjects: 451
Study 38985475 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 451
Study 38985480 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-stage Turnbull-Cutait pull-through hand-sewn coloanal anastomosis
Number of subjects: 92
Study 38985480 — intervention group
Group type: COMPARATOR
Intervention: Standard hand-sewn coloanal anastomosis associated with diverting ileostomy
Number of subjects: 92
Study 38985488 — intervention group
Group type: EXPERIMENTAL
Intervention: 81 mg aspirin daily
Number of subjects: 15076
Study 38985488 — intervention group
Group type: EXPERIMENTAL
Intervention: 325 mg aspirin daily
Number of subjects: 15076
Study 38985492 — intervention group
Group type: EXPERIMENTAL
Intervention: Active aiTBS (10 sessions per day for 5 days, 90% resting motor threshold, 90,000 pulses total)
Number of subjects: 24
Study 38985492 — intervention group
Group type: COMPARATOR
Intervention: Sham aiTBS (10 sessions per day for 5 days, 90% resting motor threshold, 90,000 pulses total)
Number of subjects: 24
Study 38985496 — intervention group
Group type: EXPERIMENTAL
Intervention: Z1 REBOA
Number of subjects: 16
Study 38985496 — intervention group
Group type: EXPERIMENTAL
Intervention: Z1 P-REBOA
Number of subjects: 16
Study 38985496 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 16
Study 38985561 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezafungin (400 mg/200 mg once-weekly)
Number of subjects: 84
Study 38985561 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (70 mg/50 mg once-daily)
Number of subjects: 84
Study 38985746 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor training alone
Number of subjects: 0
Study 38985746 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-based cognitive rehabilitation combined with motor training
Number of subjects: 0
Study 38985746 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital-based cognitive rehabilitation coupled with motor training
Number of subjects: 0
Study 38985746 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38985785 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose azithromycin for 1-5 month-olds during trachoma MDA
Number of subjects: 1735
Study 38985785 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-MDA coverage survey
Number of subjects: 1735
Study 38985785 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative data from parents, CDDs, and supervisors
Number of subjects: 1735
Study 38985796 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofol
Number of subjects: 136
Study 38985796 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 136
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 gas-based cryotherapy
Number of subjects: 864
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gas cryotherapy
Number of subjects: 864
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal ablation (TA)
Number of subjects: 864
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to post-treatment recommendations
Number of subjects: 864
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of gynecologic infection
Number of subjects: 864
Study 38985817 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-gas cryotherapy and TA
Number of subjects: 864
Study 38985849 — intervention group
Group type: EXPERIMENTAL
Intervention: TARE/Chemo
Number of subjects: 303
Study 38985849 — intervention group
Group type: COMPARATOR
Intervention: Chemo
Number of subjects: 303
Study 38985979 — intervention group
Group type: EXPERIMENTAL
Intervention: LIS1 (0.6, 1, 3, 6, 8, or 10 mg/kg)
Number of subjects: 10
Study 38985979 — intervention group
Group type: EXPERIMENTAL
Intervention: LIS1 (8 mg/kg and 10 mg/kg)
Number of subjects: 10
Study 38985979 — intervention group
Group type: EXPERIMENTAL
Intervention: LIS1
Number of subjects: 10
Study 38985986 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-LRTI<2Y
Number of subjects: 1395
Study 38986058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nirsevimab therapy
Number of subjects: 1035
Study 38986058 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nirsevimab)
Number of subjects: 1035
Study 38986134 — intervention group
Group type: EXPERIMENTAL
Intervention: PatientCareAnywhere intervention
Number of subjects: 36
Study 38986134 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 36
Study 38986210 — intervention group
Group type: EXPERIMENTAL
Intervention: pemi/gem/cis
Number of subjects: 65
Study 38986210 — intervention group
Group type: EXPERIMENTAL
Intervention: pemi/doc
Number of subjects: 65
Study 38986210 — intervention group
Group type: EXPERIMENTAL
Intervention: pemi/tras
Number of subjects: 65
Study 38986210 — intervention group
Group type: EXPERIMENTAL
Intervention: pemi/pembro
Number of subjects: 65
Study 38986210 — intervention group
Group type: EXPERIMENTAL
Intervention: pemi/reti
Number of subjects: 65
Study 38986212 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 15
Study 38986421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D)
Number of subjects: 144
Study 38986421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib 400 mg bid plus nazartinib 100 mg qd (RP2D) in group 1 + phase 1b RP2D
Number of subjects: 144
Study 38986421 — intervention group
Group type: EXPERIMENTAL
Intervention: Capmatinib plus nazartinib
Number of subjects: 144
Study 38986541 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mL of 24% sucrose administered 2 min prior to painful procedures
Number of subjects: 172
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQol five-dimension five-level (EQ5D-5L)
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrointestinal Quality Life Index-36
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Health Questionnaire-9
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalised Anxiety Disorder 7
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: International Trauma Questionnaire
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver Interaction Scale
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Severity Scale
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with patient participants
Number of subjects: 160
Study 38986553 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with family caregivers
Number of subjects: 160
Study 38986555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Navigation (PN) intervention, which includes a postal appointment notification and a prearranged telephone appointment with a pathway navigator.
Number of subjects: 0
Study 38986555 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathway Navigation (PN) intervention
Number of subjects: 0
Study 38986555 — intervention group
Group type: COMPARATOR
Intervention: Usual care (a further postal invitation to contact the screening service for a lung health check)
Number of subjects: 0
Study 38986575 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment plans
Number of subjects: 25
Study 38986575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-led decisions
Number of subjects: 25
Study 38986575 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication adjuncts
Number of subjects: 25
Study 38986575 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aids
Number of subjects: 25
Study 38986575 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetition of information
Number of subjects: 25
Study 38986608 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg/kg HLX22 + HLX02 + XELOX (group A)
Number of subjects: 53
Study 38986608 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg HLX22 + HLX02 + XELOX (group B)
Number of subjects: 53
Study 38986608 — intervention group
Group type: COMPARATOR
Intervention: Placebo + HLX02 + XELOX (group C)
Number of subjects: 53
Study 38986608 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (A, B, C)
Number of subjects: 53
Study 38986627 — intervention group
Group type: EXPERIMENTAL
Intervention: 240mL of coffee with 6mg/caffeine/kg of weight
Number of subjects: 0
Study 38986627 — intervention group
Group type: COMPARATOR
Intervention: 240mL of water
Number of subjects: 0
Study 38986667 — intervention group
Group type: EXPERIMENTAL
Intervention: Aldose reductase inhibitor
Number of subjects: 691
Study 38986791 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 139
Study 38986791 — intervention group
Group type: EXPERIMENTAL
Intervention: Common side effect treatments (acetaminophen, loperamide, ondansetron)
Number of subjects: 139
Study 38986891 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 76
Study 38986891 — intervention group
Group type: COMPARATOR
Intervention: Placebo control, mock laser (ML) acupuncture
Number of subjects: 76
Study 38986891 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EA and ML)
Number of subjects: 76
Study 38987020 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic robotic abdominal surgery
Number of subjects: 0
Study 38987020 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic non-robotic abdominal surgery
Number of subjects: 0
Study 38987228 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (intravenous infusion, once weekly for 4 weeks) with IVIg treatment
Number of subjects: 57
Study 38987228 — intervention group
Group type: COMPARATOR
Intervention: Placebo with IVIg treatment
Number of subjects: 57
Study 38987291 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed meal tolerance test (MMTT)
Number of subjects: 501
Study 38987291 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after median time 9.6 years
Number of subjects: 501
Study 38987318 — intervention group
Group type: EXPERIMENTAL
Intervention: SVF isolated by the new clinical protocol
Number of subjects: 13
Study 38987318 — intervention group
Group type: COMPARATOR
Intervention: SVF isolated by the laboratory protocol
Number of subjects: 13
Study 38987363 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (120 or 160 mg daily) given from day 4 to day 10 of each 14-day cycle of FOLFIRINOX (including oxaliplatin, folinic acid, fluorouracil, and irinotecan at 150 or 180 mg/m²)
Number of subjects: 13
Study 38987407 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy School Start intervention
Number of subjects: 353
Study 38987421 — intervention group
Group type: EXPERIMENTAL
Intervention: AMH ≥ 1.1 ng/mL
Number of subjects: 245
Study 38987421 — intervention group
Group type: COMPARATOR
Intervention: AMH < 1.1 ng/mL
Number of subjects: 245
Study 38987667 — intervention group
Group type: EXPERIMENTAL
Intervention: Head rotation technique
Number of subjects: 158
Study 38987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge letter content with at least five of eleven key elements coded using an assessment matrix and deductive content analysis.
Number of subjects: 136
Study 38987669 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge letters containing all eleven key elements.
Number of subjects: 136
Study 38987671 — intervention group
Group type: EXPERIMENTAL
Intervention: FX CorAL 600
Number of subjects: 82
Study 38987671 — intervention group
Group type: COMPARATOR
Intervention: FX CorDiax 600
Number of subjects: 82
Study 38987671 — intervention group
Group type: COMPARATOR
Intervention: xevonta Hi 15
Number of subjects: 82
Study 38987676 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized care program
Number of subjects: 50
Study 38987676 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 50
Study 38987696 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal cardiopulmonary resuscitation (ECPR)
Number of subjects: 648
Study 38987721 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based filming for General Movement Assessment (GMA)
Number of subjects: 102
Study 38987721 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based filming for General Movement Assessment (GMA)
Number of subjects: 102
Study 38987721 — intervention group
Group type: EXPERIMENTAL
Intervention: Home filming experience
Number of subjects: 102
Study 38987721 — intervention group
Group type: EXPERIMENTAL
Intervention: Concerns about child development after home filming
Number of subjects: 102
Study 38987721 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of home video for GMA
Number of subjects: 102
Study 38987737 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy incorporating horses (PIH) during 15 sessions once a week.
Number of subjects: 35
Study 38987784 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme-Q10 (240 mg daily)
Number of subjects: 60
Study 38987786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined usage of povidone-iodine irrigation and topical vancomycin powder before wound closure
Number of subjects: 840
Study 38987786 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine irrigation alone before wound closure
Number of subjects: 840
Study 38987812 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepare Romania (culturally adapted counseling and mobile health intervention)
Number of subjects: 120
Study 38987812 — intervention group
Group type: COMPARATOR
Intervention: PrEP education control arm
Number of subjects: 120
Study 38988185 — intervention group
Group type: EXPERIMENTAL
Intervention: Govorestat 5 mg/kg
Number of subjects: 95
Study 38988185 — intervention group
Group type: EXPERIMENTAL
Intervention: Govorestat 20 mg/kg
Number of subjects: 95
Study 38988185 — intervention group
Group type: EXPERIMENTAL
Intervention: Govorestat 40 mg/kg
Number of subjects: 95
Study 38988185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 38988248 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative transthoracic echocardiography (TTE) recommendations
Number of subjects: 15529